Article Information
vol. 6 no. 4
Published By
Online ISSN
History
- Received June 20, 2020
- Accepted October 27, 2020
- Published online December 7, 2020.
Article Versions
- previous version (November 6, 2020 - 08:46).
- You are viewing the most recent version of this article.
Copyright & Usage
Copyright ©ERS 2020 This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.
Author Information
- Rahul Kumar1⇑,
- Michael H. Lee1,
- Claudia Mickael2,
- Biruk Kassa1,
- Qadar Pasha3,
- Rubin Tuder2 and
- Brian Graham1
- 1Dept of Medicine, Division of Pulmonary and Critical Care Medicine, University of California San Francisco, San Francisco, CA, USA
- 2Dept of Medicine, Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA
- 3Functional Genomics Unit, CSIR-Institute of Genomics and Integrative Biology, Delhi, India
- Rahul Kumar, Pulmonary and Critical Care Medicine, University of California San Francisco, San Francisco, CA 94110, USA. E-mail: rahul.kumar2{at}ucsf.edu
Funding
Pulmonary Hypertension Association
National Heart, Lung, and Blood Institute
P01HL014985; P01HL152961; R01HL135872American Heart Association
19CDA34730030
Article usage
Altmetrics
Vol 6 Issue 4
Table of Contents
Pathophysiology and potential future therapeutic targets using preclinical models of COVID-19
Jump To
- Article
- Abstract
- Abstract
- Introduction
- Origin of SARS-COV-2 and mode of transmission to humans
- ACE2: a portal of entry for SARS-CoV-2
- Role of animal models in elucidating the pathogenesis of COVID-19
- The pulmonary pathophysiology of COVID-19
- Potential molecular and biochemical therapeutic targets in the host
- Footnotes
- References
- Figures & Data
- Info & Metrics